Valuation: HLS Therapeutics Inc.

Market Cap 91.75M 80.18M 73.99M 68.2M 129M 8.84B 131M 884M 348M 4.33B 345M 337M 14.9B P/E 2026 *
-14.7x
P/E 2027 * -97.8x
Enterprise Value 91.75M 80.18M 73.99M 68.2M 129M 8.84B 131M 884M 348M 4.33B 345M 337M 14.9B EV / Sales 2026 *
1.58x
EV / Sales 2027 * 1.43x
Free-Float
99.47%
Yield 2026 *
-
Yield 2027 * -
1 day-1.20%
1 week-4.64%
Current month-6.80%
1 month-6.38%
3 months-11.61%
6 months-12.18%
Current year-14.73%
1 week 4.11
Extreme 4.11
4.3
1 month 4
Extreme 4
4.99
Current year 4
Extreme 4
5.25
1 year 4
Extreme 4
5.76
3 years 3
Extreme 3
6.54
5 years 3
Extreme 3
20.52
10 years 3
Extreme 3
25.92
Manager TitleAgeSince
Chief Executive Officer 58 30/04/2023
Director of Finance/CFO 61 25/01/2024
Chief Tech/Sci/R&D Officer 61 31/05/2014
Director TitleAgeSince
Director/Board Member 58 11/03/2018
Chairman 48 21/06/2023
Director/Board Member 65 31/12/2020
Date Insider Type Main position Quantity % Market Cap.
26/06/26 Option

Chief Financial Officer

50,000 0.1599%
26/06/26 Option

Head of Human Resources

10,000 0.0320%
26/06/26 Option

Controller/Auditor

10,000 0.0320%
Change 5-day change 1-year change 3-year change Capi.($)
-1.20%-4.64%-16.29%-39.47% 91.75M
+0.01%+4.40%+18.46%+104.38% 98.51B
-0.09%-3.09%+43.31%+144.48% 53.52B
-0.34%+3.90%+5.40%+283.01% 23.53B
-2.52%+2.98%-13.40%-21.43% 8.25B
-5.82%+2.45%-31.50%-31.90% 7.79B
-1.35%+5.02%-6.44%-25.07% 6.99B
+2.44%+0.89%+25.25%+34.78% 6.31B
+0.79%+2.77%-0.17%+25.74% 5.51B
-2.29%+2.00%-5.37%-5.93% 3.76B
Average -1.04%+1.61%+1.92%+46.86% 21.43B
Weighted average by Cap. -0.36%+2.37%+18.66%+113.93%

Financials

2026 *2027 *
Net sales 58.03M 50.71M 46.8M 43.13M 81.3M 5.59B 83.1M 559M 220M 2.74B 218M 213M 9.42B 64.31M 56.2M 51.86M 47.8M 90.1M 6.19B 92.1M 620M 244M 3.03B 242M 236M 10.44B
Net income -6.26M -5.47M -5.05M -4.66M -8.78M -603M -8.97M -60.38M -23.75M -295M -23.53M -23.01M -1.02B -1.05M -918K -847K -780K -1.47M -101M -1.5M -10.12M -3.98M -49.52M -3.94M -3.86M -170M
Net Debt - -
Logo HLS Therapeutics Inc.
HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules are a single-molecule prescription product for the treatment of cardiovascular disease.
Employees
85
Date Price Change Volume
17/07/26 CA$4.110 -1.20% 5,100
16/07/26 CA$4.160 -0.95% 13,214
15/07/26 CA$4.200 +1.45% 500
14/07/26 CA$4.140 -2.13% 9,010
13/07/26 CA$4.230 -1.86% 2,300
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
2.934USD
Average target price
5.179USD
Spread / Average Target
+76.54%

Quarterly revenue - Rate of surprise